Ovarian Cancer Staging, Prognostic Factors and Management

A 48-year-old woman from Mumbai undergoes total abdominal hysterectomy, bilateral salpingo-oophorectomy, and optimal cytoreduction for Stage IIIC high-grade serous ovarian cancer. Postoperatively, she receives 6 cycles of intravenous paclitaxel and carboplatin. At 18 months follow-up, she develops a rising CA-125 (from 12 to 145 U/mL over 2 months) and imaging shows a 3 cm pelvic mass. She is asymptomatic. What is the most appropriate next step in management?

A 58-year-old woman with stage IIIC ovarian cancer (FIGO 2014) undergoes primary cytoreductive surgery followed by neoadjuvant chemotherapy with paclitaxel and carboplatin. After 3 cycles, imaging shows residual disease of 1.2 cm. She completes 6 cycles total. Which of the following represents the strongest prognostic factor for her overall survival in this scenario?

A 52-year-old woman with newly diagnosed stage IIIC epithelial ovarian cancer (high-grade serous carcinoma) has completed optimal cytoreductive surgery. What is the drug of choice for first-line adjuvant chemotherapy?

A 48-year-old woman undergoes primary cytoreductive surgery for stage IIIC ovarian cancer. Intraoperative findings reveal extensive peritoneal carcinomatosis, omental caking, and involvement of the small bowel mesentery. Histology confirms high-grade serous adenocarcinoma. To assess for homologous recombination deficiency (HRD) status and guide platinum-based chemotherapy and PARP inhibitor eligibility, which investigation should be performed on the tumor tissue?

A 52-year-old postmenopausal woman is diagnosed with epithelial ovarian cancer. After staging investigations, she is found to have Stage III disease. Which is the most common histological type of ovarian cancer in this patient?